On February 9, 2024, Invivyd, Inc., a biopharmaceutical company based in Delaware, filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission (SEC). The registration pertains to the potential sale of up to 37,745,998 shares of common stock by selling stockholders. This includes 30,921,286 issued and outstanding shares and 6,824,712 shares issuable upon the exercise of an outstanding common stock purchase warrant. Invivyd will not sell any shares nor receive proceeds from the stockholders' sales. However, the company may receive proceeds from the exercise of the warrant, which could total approximately $23.75 million if exercised for cash. These proceeds would be used for working capital and general corporate purposes. The selling stockholders may sell the shares at market prices or negotiated transactions...Show More

On February 9, 2024, Invivyd, Inc., a biopharmaceutical company based in Delaware, filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission (SEC). The registration pertains to the potential sale of up to 37,745,998 shares of common stock by selling stockholders. This includes 30,921,286 issued and outstanding shares and 6,824,712 shares issuable upon the exercise of an outstanding common stock purchase warrant. Invivyd will not sell any shares nor receive proceeds from the stockholders' sales. However, the company may receive proceeds from the exercise of the warrant, which could total approximately $23.75 million if exercised for cash. These proceeds would be used for working capital and general corporate purposes. The selling stockholders may sell the shares at market prices or negotiated transactions, and the sales may be made on the Nasdaq Global Market, where Invivyd's stock trades under the ticker symbol 'IVVD'. The last reported sale price of Invivyd's common stock was $5.04 per share as of February 8, 2024. Invivyd is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.